I wish Acadia would get their A into G and start the ball rolling to offer NNZ2591 to Retts and Fragile-X sufferers. Perhaps they are waiting for more success with Neurens current trials for NNZ2591, but surely it makes sense being the "superior" drug with little or no side-effects.... watch this space... Daybue II is coming.
I wish Acadia would get their A into G and start the ball...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.31 |
Change
0.490(2.60%) |
Mkt cap ! $2.465B | |||
| Open | High | Low | Value | Volume |
| $19.14 | $19.43 | $18.88 | $7.696M | 400.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1100 | $19.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.33 | 252 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.35 |
Change
0.490 ( 2.80 %) |
||||
| Open | High | Low | Volume | ||
| $19.14 | $19.42 | $18.88 | 94185 | ||
| Last updated 15.59pm 13/06/2024 ? | |||||
| NEU (ASX) Chart |